Clinical study of high-dose Atorvastatin on peripheral blood nuclear factor kappa B in patients with acute coronary syndrome complicated with diabetes mellitus
ZENG Hui1 LIU Jun-min1▲ LIN Bo-li2
1.Department of Cardiovascular Medicine,Ningdu County People′s Hospital，Ganzhou City,Jiangxi Province,Ningdu 342800,China;
2.Department of Cardiovascular Medicine,Xinfeng County People′s Hospital,Ganzhou City,Jiangxi Province,Xinfeng 341600,China
Abstract：Objective To explore the influence of high-dose Atorvastatin on peripheral blood nuclear factor-kappa B(NF-κB)in patients with acute coronary syndrome(ACS)complicated with diabetes mellitus(DM).Methods From June 2015 to May 2017,100 ACS patients complicated with DM admitted into our hospital were selected and evenly divided into control group (n=50)and experimental group (n=50)in random.Participants in both groups were provided with Atorvastatin for treatment,but with different doses.In the control group,the dose was 10 mg/d,while in the experimental group,the dose was 40 mg/d.The serum biochemical test and the expression and detection of NF-κB were performed before and 4 weeks after the experiment.In addition,the incidence of cardiovascular events was calculated.Results After therapy,the levels of NF-κB,hs-CRP,IL-6,and TNF-α in the two group were all decreased to some extent,and the decrease in the experimental group was more remarkable than that in the control group,which was displayed a statistical inter-group difference(P＜0.05).In the control group,the incidence of cardiovascular events was 20.00%,while 4.00%in the experimental group with a statistical difference(P＜0.05).Conclusion In the treatment of ACS complicated with DM,high-dose Atorvastatin can significantly inhibit NF-κB activity,attenuate inflammation reactions,relieve clinical symptoms,and reduce the incidence of cardiovascular events with an affirmative clinical value.
京公网安备 11010502046607号